1. Immunology/Inflammation
  2. Interleukin Related
  3. Tocilizumab

Tocilizumab  (Synonyms: Anti-Human IL6R, Humanized Antibody)

Cat. No.: HY-P9917 Purity: 98.00%
COA

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

For research use only. We do not sell to patients.

Tocilizumab Chemical Structure

Tocilizumab Chemical Structure

CAS No. : 375823-41-9

Size Price Stock Quantity
1 mg USD 280 In-stock
5 mg USD 670 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 18 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

IC50 & Target[1][2]

IL-6

 

In Vitro

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.
In Vivo

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage: 1.0 mg/100 μL
Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result: Led the volume of each metastatic focus significantly smaller.
Animal Model: SCID mice with SAS cells[3]
Dosage: 100 μg/mL
Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result: Suppressed the growth of advanced tumors.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tocilizumab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 99.67%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tocilizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tocilizumab
Cat. No.:
HY-P9917
Quantity:
MCE Japan Authorized Agent: